Tradename
(indomethacin) for injection
NDA 22-536

Summary Basis for Recommended Action
From Chemistry, Manufacturing, and Controls

Applicant: APP Pharmaceutical, LLC
1501 East Woodfield Road,
Schaumberg, IL 60173

Indication: Indicated to close a hemodynamically significant patent ductus arteriosus in premature infants.

Presentation: Lyophilized, white to yellow powder or plug supplied in a 3 cc vial as 1 mg indomethacin. The product is to be reconstituted prior to administration.

EER Status: Acceptable, 22-Jun-09

Consults: Methods Validation – Revalidation by Agency was not requested.
EA – categorical exclusion granted
Microbiology: Acceptable

II. Summary of Chemistry Assessments

Drug Substance:

Indomethacin is a white to yellow, crystalline powder with a mol weight of 357.80 which is practically insoluble in water and slightly soluble in alcohol, chloroform and ether. The molecular formula is C_{19}H_{16}ClNO_{4}. Chemically, indomethacin is 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic-acid. Indomethacin can exist in more than one polymorphic form. However, a thermodynamically stable is produced for this product. The CMC information for the drug substance is referenced to DMF, held by . The DMF was previously reviewed and found to be adequate to support NDA submissions. The applicant has provided specification for accepting the incoming lots of the drug substance. The specification includes test and acceptance limit for identification (IR, UV and X-ray), loss on drying, residue on ignition, heavy metals, residual solvents (GC), assay (HPLC), impurities (HPLC), microbial burden and bacterial endotoxin.
Conclusion: Acceptable.

Drug product: The drug product is a single-use, sterile, lyophilized powder that is reconstituted prior to administration. Excipients used in the formulation, sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous, sodium hydroxide, hydrochloric acid and water for injection are all compendial grade. The drug product manufacturing is fairly simple that involve filling and lyophilization. The drug product specification includes test and acceptance limit for description, pH, color, container/closure integrity, uniformity of dosage units by content uniformity, identification, assay (HPLC), impurities (HPLC), particulate matter, sterility, bacterial endotoxin and statement of compliance to <USP 467>. The specification also includes testing for reconstitution time, completeness of dissolution, clarity of solution, particulate matter and visual color for the reconstituted solution. All non-USP analytical procedures are adequately validated.

The microbiological quality of the product was reviewed by the NDMS reviewer and a final acceptable recommendation has been made by the reviewer.

Based on the available data a shelf life of 24 months may be granted for the product when stored under controlled room temperature.

Overall conclusion: The CMC related issues have been resolved. The application is recommended for approval from CMC perspective.

Additional Items: None

Ramesh Sood, Ph.D.
Branch Chief/DPA1/Branch 1/ONDQA
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-22536</td>
<td>ORIG-1</td>
<td>APP PHARMACEUTICA LS LLC</td>
<td>INDOMETHACIN</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAMESH K SOOD
03/18/2010
NDA 22-536

Indomethacin For Injection

APP Pharmaceuticals, LLC

Thomas M. Wong, Ph.D.
Division of Pre-Marketing Assessment I
Office of New Drug Quality Assessment

Division of Cardiovascular and Renal Products
Review of Chemistry, Manufacturing, and Controls
# Table of Content

I. **Recommendations** ........................................................................................................... 7  
   A. Recommendation and Conclusion on Approvability ............................................................ 7  
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable ........................................................................ 7  

II. **Summary of Chemistry Assessments** ........................................................................... 7  
   A. Description of the Drug Product(s) and Drug Substance(s) ................................................... 7  
   B. Description of How the Drug Product is Intended to be Used ............................................... 8  
   C. Basis for Approvability or Not-Approval Recommendation ................................................ 8  

III. **Administrative** ........................................................................................................... 8  
   A. Reviewer’s Signature ........................................................................................................ 8  
   B. Endorsement Block ......................................................................................................... 8  
   C. C Block .......................................................................................................................... 8  

I. **Review Of Common Technical Document-Quality (Ctd-Q)** .................................. 9  
   S DRUG SUBSTANCE ................................................................................................................. 9  

P. **DRUG PRODUCT** ......................................................................................................... 20  
   A APPENDICES ....................................................................................................................... 90  
   R REGIONAL INFORMATION .................................................................................................. 90  

II. **Review Of Common Technical Document-Quality (Ctd-Q)** .......................... 91  
   A Labeling & Package Insert .................................................................................................. 91  

III. **List Of Deficiencies To Be Communicated** ................................................................. 97
Chemistry Review Data Sheet

1. NDA 22-536

2. REVIEW #: 1

3. REVIEW DATE: Nov 24, 2009

4. REVIEWER: Thomas M. Wong, Ph.D.

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>8 May 2009</td>
</tr>
<tr>
<td>CMC Amendment # 0003:</td>
<td>8 Oct 2009</td>
</tr>
<tr>
<td>CMC Amendment # 0004:</td>
<td>10 Nov 2009</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

Name: APP Pharmaceuticals, LLC
1501 East Woodfield Road
Suite 300 East
Schaumberg IL 60173

Representative: Not Applicable

Telephone: (847) 969-2700

8. DRUG PRODUCT NAME/CODE/TYPE:

a) Proprietary Name: None
b) Non-Proprietary Name (USAN): Indomethacin
c) Code Name/#: N/A
d) Chem. Type/Submission Priority (ONDC only):
   - Chem. Type: 3
   - Submission Priority: S
9. LEGAL BASIS FOR SUBMISSION: 505(b)(2) Indomethacin for Injection, 1 mg/vial.

10. PHARMACOL. CATEGORY: To close a hemodynamically significantly patent ductus arteriosus in premature infants.

11. DOSAGE FORM: Injection

12. STRENGTH/POTENCY: 1 mg/vial

13. ROUTE OF ADMINISTRATION: Intravenous

14. Rx/OTC DISPENSED: X Rx ___ OT C

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
   _____ SPOTS product – Form Completed
   X ___ Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

   USAN Name: Indomethacin, USP
   Chemical name: 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic-acid
   Other chemical name: 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-
   CAS registry number: 53-86-1
   Company or lab code: None
   Molecular Weight: 357.80
   Structural formula: C_{19}H_{16}ClNO_{4}
   Structure: [diagram]

Page 4 of 100
17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td>Adequate</td>
<td>17-Jun-2009</td>
<td>Reviewed by Sulene X Han and was found adequate</td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td>Sufficient information in application</td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td>Adequate</td>
<td>12-Nov-2006</td>
<td>Reviewed by Milagros Salazar Driver and was found adequate</td>
</tr>
</tbody>
</table>

1 Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)
Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indocin® I.V., Ovation Pharmaceuticals</td>
<td>Not provided</td>
<td>Reference Listed Drug (RLD)</td>
</tr>
</tbody>
</table>

18. STATUS:

**ONDC:**

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>Acceptable</td>
<td>22-JUN-09</td>
<td>Office of Compliance</td>
</tr>
<tr>
<td>Biopharm</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LNC</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMFPA</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microbiology</td>
<td>Acceptable/categorical exclusion</td>
<td>As per this review</td>
<td>Thomas M. Wong, Ph.D.</td>
</tr>
</tbody>
</table>

**OGD:**

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microbiology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioequivalence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiopharmaceutical</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. ORDER OF REVIEW (OGD Only)

The application submission(s) covered by this review was taken in the date order of receipt. ____

Yes  ____  No  ____  If no, explain reason(s) below:
The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

The CMC of the drug product, Indomethacin for Injection 1 mg, has been reviewed and all deficiencies have been resolved. There is no CMC outstanding issues pending. At this time we are waiting for microbiology recommendation. A final memo will be deposited in the DARRTS once recommendation from microbiology review is obtained.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

None at this time.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Drug product:
Indomethacin for injection is a cardiovascular drug and is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective. The product is a sterile, lyophilized, white to yellow powder supplied as single dose vials containing 1 mg of indomethacin in a 3 c.c. vial. It is intended for I.V. injection upon reconstitution with water for injection or 0.9% sodium chloride injection. The reconstituted solution, pH 6.0 to 7.5, is clear, slightly yellow and essentially free from visible particles. Indomethacin for injection contains the following excipients: 0.29 mg monobasic sodium phosphate, 0.41 mg dibasic sodium phosphate, and 0.24 mg sodium hydroxide. The pH specification of the product does not meet the current USP standard. The applicant has incorporated the following statement in the carton label and the package insert: The pH of the product does not meet the USP monograph [FD&C Act Chapter V, SEC. 501. [21USC §351](b)]. Available 12 months stability data supports 24-month expiration dating period for the indomethacin for injection when stored at 25°C (77°F) and protect from light. Excursions permitted to 15° to 30°C (59° to 86°F).

Drug substance:
Detailed information of the drug substance is available in . Indomethacin, USP, is a white to yellow crystalline powder with a molecular weight of 357.80. The molecular formula is C_{19}H_{16}ClNO_{4} Chemically, indomethacin is 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic-acid. It is practically insoluble in water, slightly soluble in alcohol, chloroform and in ether. Indomethacin exists in more than one polymorphic form. However, the thermodynamically stable is produced as confirmed by X-ray diffraction and IR spectrophotometry and the IR spectrum conforms to the IR spectrum of a similar preparation of USP indomethacin RS. Specification of the drug substance is in place. There are two actual impurities arising from the synthesis of the drug substance, namely, and The HPLC testing method is an alternative method which is
different from the USP regulatory methods and has been validated. The available stability data supports a 5 year expiry dating.

B. Description of How the Drug Product is Intended to be Used

Indomethacin for injection is a sterile, lyophilized, white to yellow powder product. Upon reconstitution with water for injection or 0.9% sodium chloride injection, it is administered intravenously for the indication of closing a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g.

Indomethacin for injection is supplied as single dose vials containing 1 mg of indomethacin in a 3 c.c. vial. Each vial is individually packed in a carton. The drug product is to be stored at 25°C (77°F) with excursions permitted to 15° to 30°C (59° to 86°F). Protect from light. The product number is 605903 and the NDC is 63323-659-03.

C. Basis for Approvability or Not-Approval Recommendation

From a CMC perspective, APP Pharmaceuticals, LLC, has submitted sufficient and appropriate information to support the approval of the drug product, Indomethacin for Injection.

III. Administrative

A. Reviewer’s Signature
   See electronic signatures in DFS.

B. Endorsement Block

Chemist Name: Thomas M. Wong, Ph.D.
Branch Chief Name: Ramesh Sood, Ph.D.
Project Manager Name:

C. C Block
   See DFS.

92 Page(s) has been Withheld in Full immediately following this page as B4 (CCI/TS)
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-22536</td>
<td>ORIG-1</td>
<td>APP PHARMACEUTICA LS LLC</td>
<td>INDOMETHACIN</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THOMAS M WONG
11/24/2009

RAMESH K SOOD
11/24/2009
Summary
This 505(b)(2) NDA, in eCTD format, is for a lyophilized formulation of indomethacin for injection. The reference listed product is Ovation Pharmaceutical’s Indocin IV, NDA 18-878. The route of administration, dosage form and strength of the proposed drug product are the same as those for Indocin IV. The RLD uses indomethacin sodium salt as the drug substance whereas this NDA uses indomethacin free acid. The RLD has no other excipients other than water for injection which is removed during lyophilization. In this NDA, the sodium salt of indomethacin is formed in situ with sodium hydroxide and phosphate buffers are used to maintain the pH between \(7.1\) and \(7.2\) in the manufacturing procedure. Hydrochloric acid may also be used for final pH adjustment to 7.2. There is no IND application associated with this NDA and no meetings have been held with the Applicant.

Drug Substance
Indomethacin is a white to yellow crystalline powder which is practically insoluble in water and slightly soluble in alcohol, chloroform and ether. All CMC information for this drug substance is cross-referenced to (b)(4), held by the manufacturer, (b)(4). This DMF has been previously reviewed and found to be adequate. The last review, dated Feb. 18, 2009, was of an annual report. There is an USP monograph for indomethacin. Regulatory specifications have been provided by the Applicant which follow USP except for the use of an alternate HPLC method for assay, the inclusion of specified impurities and tests for microbial bioburden and bacterial endotoxins. (b)(4) are the residual solvents which are monitored. It is claimed that indomethacin manufactured by (b)(4) is the thermodynamically stable crystalline (b)(4) which conforms to the USP indomethacin RS by X-ray diffraction pattern and IR spectrum. The retest period for the drug substance is set not to exceed the manufacturer’s expiration of 5 years.
Drug Product
This is a sterile lyophilized product containing 1 mg indomethacin in a 3mL vial. Excipients used in the formulation, sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous, sodium hydroxide, hydrochloric acid and water for injection are all compendial grade. The product is manufactured by APP in Puerto Rico using standard procedures for a sterile lyophilized dosage form. Indomethacin is initially dissolved in water for injection containing the excipients while maintaining a pH between . The pH is then adjusted to 7.2. The container/closure is a 3 mL Type I glass vial with 13 mm stopper and 13 mm flip cap aluminum crimp seal.

The product specification contains the usual test attributes for a sterile lyophilized solid. There is an USP monograph for indomethacin for injection which is based on indomethacin sodium drug substance. The APP product meets these specifications except for pH and so will not be labeled with the USP designation. The Applicant will use an in-house method rather than the USP method for assay and impurities. Stability data have been provided for 3 full-scale batches stored under accelerated and long term conditions. 6 months’ accelerated and long term data are available for all batches. 9 and 12 months’ data have been submitted for two of the batches at 25°C/60% RH. It is stated that updated stability data for 12 months will be submitted in an amendment as soon as they are available. A 2 year expiry is proposed.

Critical Review Issues

Drug substance
- It is stated that indomethacin has different morphic forms which can be distinguished by X-ray diffraction and IR spectroscopy. Do these forms exhibit different solubilities and does the manufacturing process consistently produce only one form?
- Should the HPLC method for assay be designated an alternate method in the specification since the USP method is considered the regulatory method?
- Is the proposed limit for justified from a safety perspective?
- It is not clear why the two degradation products, and are specified with different limits since both are formed simultaneously by hydrolysis of indomethacin.
- What is the retest period for the drug substance? It is claimed that the manufacturer has assigned an expiration date of 5 years.

Drug Product
- Since this is a parenteral dosage form, the major critical issue is sterility assurance of the product after manufacture and maintenance of sterility over the shelf-life. These aspects are expected to be covered by the microbiology reviewer.
- Are all excipients tested for residual solvents or is certification provided that no organic solvents are used their manufacture?
- Is the justification provided for excluding determination of water content at release or on stability acceptable?
- Should reconstitution time be part of the specification?
• Is it sufficient to state “meets specifications” for the batch results for Uniformity of Dosage Units?
• Is the limit for Total Impurities acceptable?
• Is the pH range of 6.0-7.5% justified considering the release and stability data and the finding that the product is most stable in the pH range 7.0-7.5?
• It is stated that the Container/Closure Integrity test will be performed in the stability studies in lieu of sterility—is this acceptable? Is the ICP method adequate for this purpose? (These issues may be covered in the Microbiology review).
• There is no provision for testing under accelerated conditions in the post-approval stability protocol for the first 3 commercial batches.

Labeling
• The statement on the container labels does not seem to be relevant to this product—it is relevant to the RLD where the 1 mg strength refers to indomethacin whereas the sodium salt is used in the formulation.
• The PI gives the structure of indomethacin sodium salt for the drug substance. This is not correct since indomethacin is the drug substance for this NDA and the sodium salt is only formed in situ.
• The storage conditions on the labels should be revised to reflect current practice.

Comments and Recommendations
The application is fileable. Manufacturing, testing and packaging facilities have been entered into EES and the reviewer should verify the accuracy and completeness of the entries. A microbiology reviewer has been assigned to this NDA. A single CMC reviewer is recommended for this application.

Kasturi Srinivasachar
Pharmaceutical Assessment Lead
Jun. 18, 2009

Ramesh Sood, Ph.D.
Branch Chief
Jun. 18, 2009
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Kasturi Srinivasachar
6/18/2009 12:30:11 PM
CHEMIST

Ramesh Sood
6/18/2009 12:44:51 PM
CHEMIST